Year: 2023
Type: article
Abstract: A clinical trial of nivolumab in 10 patients with pediatric cancer with high tumor mutational burden demonstrated complete responses in 50% of patients. This result recapitulates multiple clinical trial results in high mutation-burden adult cancers and may redefine best practice in the setting of germline DNA mismatch repair-based susceptibility. See related article by Das et al., p. 4770.
Source: Clinical Cancer Research
Author: Elaine R. Mardis
Institutions: Nationwide Children's Hospital, The Ohio State University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4386910000